Monoclonal Antibodies in the Treatment of Leukemia

Title: Monoclonal Antibodies in the Treatment of Leukemia

Volume: 5 Issue: 7

Author(s): Susan O'Brien, Maher Albitar and Francis J. Giles

Affiliation:

Keywords: Rituximab, cytotoxicity, hypertension, cyclophosphamide, Alemtuzumab

Abstract: MoAb-based therapies are evolving into the first broad-spectrum class of targeted antileukemic therapy. Developments in many areas, including computer modeling of receptors and ligands, and increasing sophistication in recombinant technologies may result in a rapid increase in the number and complexity of MoAbs available. We can anticipate an increase in the number of safer conjugates being delivered to leukemia cells. Further understanding of the in vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach.

Cite this article as:

O'Brien Susan, Albitar Maher and Giles J. Francis, Monoclonal Antibodies in the Treatment of Leukemia, Current Molecular Medicine 2005; 5 (7) . https://dx.doi.org/10.2174/156652405774641089